Evidence map›Paper›PMID 27347142›Full record

ArticleOncology letters2016

miR-154 inhibits migration and invasion of human non-small cell lung cancer by targeting ZEB2.

Xingyu Lin, Zhiguang Yang, Peng Zhang, Yunpeng Liu, Guoguang Shao

RetractedOpen access · diamondAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. MicroRNA-154 Targets the Wnt/β-Catenin Signaling Pathway Following Injury to Human Vascular Endothelial Cells by Hydrogen Peroxide.Medical science monitor : international medical journal of experimental and clinical research · 2019
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Xingyu LinDepartment of Thoracic Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.
Zhiguang YangDepartment of Thoracic Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.
Peng ZhangDepartment of Thoracic Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.
Yunpeng LiuDepartment of Thoracic Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.
Guoguang ShaoDepartment of Thoracic Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.
First Hospital of Jilin University · CNJilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emerging evidence suggests that microRNAs (miRs) play critical roles in the development and progression of non-small cell lung cancer (NSCLC). In a previous study, the present authors demonstrated that miR-154 acts as a tumor suppressor in NSCLC; however, its underlying molecular mechanism and target in NSCLC remain poorly understood. In the present study, ectopic expression of miR-154 remarkably suppressed cell migration and invasion in NSCLC cells. Zinc finger E-box binding homeobox 2 (ZEB2) was identified as a direct target of miR-154 in NSCLC cells. Furthermore, overexpression of miR-154 could decrease the expression of ZEB2 at the messenger RNA and protein levels. Ectopic expression of miR-154 also increased the levels of E-cadherin, an epithelial marker, and decreased the levels of vimentin, a mesenchymal marker, which contributed to suppress epithelial-mesenchymal transition (EMT) and to inhibit cell migration and invasion. In addition, downregulation of ZEB2 exerted similar effects to those caused by miR-154 overexpression on NSCLC cell migration and invasion, while upregulation of ZEB2 could significantly reverse the inhibitory effects on migration and invasion caused by miR-154 on NSCLC cells. These findings demonstrated that miR-154 inhibited migration and invasion of NSCLC cells by regulating EMT through targeting ZEB2, suggesting that miR-154 may be a potential anticancer therapeutic target for NSCLC.

Indexed as

invasionmigrationmiR-154non-small cell lung cancerZEB2

Identifiers

PMID27347142
PMCPMC4906674
OpenAlexW3195697977

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.